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Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is a prevalent nosocomial pathogen,
causing a wide range of diseases. The increased frequency of MRSA isolates in hospitals and
the emergence of vancomycin resistance have sparked the search for new control strategies.
This study aimed to characterize sixty-seven MRSA isolates collected from both infected patients and
asymptomatic carriers in a Spanish hospital. RAPD-PCR allowed the identification of six genetic
patterns. We also investigated the presence of genes involved in producing adhesins, toxins and
the capsule; the biofilm; and antimicrobial resistance. A notable percentage of the isolates carried
virulence genes and showed medium-high ability to form biofilms. Next, we assessed the strains’
susceptibility to two phages (phiIPLA-C1C and phiIPLA-RODI) and one endolysin (LysRODI).
All strains were resistant to phiIPLA-C1C, and most (70.2%) were susceptible to phiIPLA-RODI.
Regarding LysRODI, all strains displayed susceptibility, although to varying degrees. There was a
correlation between endolysin susceptibility and the random amplification of polymorphic DNA
(RAPD) profile or the presence of some virulence genes (fnbA, eta, etb, PVL and czr), but that was not
observed with biofilm-forming ability, strain origin or phage sensitivity. Taken together, these findings
can help to explain the factors influencing endolysin effectiveness, which will contribute to the
development of efficient therapies targeting MRSA infections.
Keywords: MRSA; bacteriophages; endolysins; hospital infections; biofilms; virulence genes
1. Introduction
The pathogenicity of Staphylococcus aureus relies on its capacity to synthetize an important number
of toxins and virulence factors, together with its ability to form biofilms [1]. On top of that, there is an
upward trend in the selection and spread of antibiotic resistance determinants amongst S. aureus strains.
All these characteristics allow this bacterium to successfully evade host defenses and conventional
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antibiotic treatment strategies [2]. It is also worth highlighting the adaptability of this pathogen,
which might, to some extent, be due to its genome plasticity. Indeed, approximately 25% of the
S. aureus chromosome consists of mobile genetic elements (MGEs), such as pathogenicity islands,
bacteriophages, chromosomal cassettes, transposons and plasmids, all of which can be acquired
by horizontal transfer between strains. Consequently, gain and loss of virulence and antimicrobial
resistance determinants may contribute to bacterial adaptability, virulence and survival in the face
of environmental challenges [3]. Perhaps in recent years, the most concerning aspect of S. aureus’s
epidemiology has been the extensive distribution of methicillin-resistant S. aureus (MRSA) strains,
which represent a serious threat to healthcare worldwide. Indeed, MRSA strains are now endemic in
many American and European hospitals (hospital-associated MRSA strains, HA-MRSA), accounting
for 29–35% of all clinical isolates [4]. Moreover, the fact that S. aureus can easily adapt to multiple
environments has likely contributed to the appearance of community-associated (CA-MRSA) and
livestock-associated (LA-MRSA) strains, which have evolved independently from HA-MRSA strains.
In terms of global epidemiology, HA-MRSA is endemic in hospitals; CA-MRSA is spreading within
the general population; and LA-MRSA is present in farms [5]. One interesting feature of MRSA
epidemiology is that, despite the general diversity of this pathogen, relatively few clonal lineages are
dominant. Moreover, an evolution with time is frequently observed, so that, in a specific geographical
area, the predominant lineages are periodically replaced by new epidemic clones [6]. Additionally, the
distribution and incidence of the prevalent clones differ between geographical regions [5]. In terms of
clinical pathology, HA-MRSA strains cause pneumonia, bacteremia, endocarditis and bone infections.
Bacteremia and endocarditis are the most serious infections, with mortality rates that can reach
up to 60% [7]. HA-MRSA is a very common cause of ventilator-associated pneumonia (VAP) and
hospital-associated pneumonia (HAP), probably the most frequent infections in critically ill patients,
with a mortality of 3–17% [8]. S. aureus is also the most common etiological agent of acute hematogenous
osteomyelitis (AHO) in pediatric patients [9]. Moreover, MRSA, MSSA (methicillin-sensitive S. aureus)
and coagulase-negative staphylococci are the most frequent pathogens in surgical site infections after
total hip and knee arthroplasty [10].
Today, the successful treatment of MRSA infections remains an unsolved challenge that requires
the evaluation of novel antimicrobials [11]. In this context, the application of bacteriophages and
phage-derived lytic proteins represents a promising strategy for both the treatment and prophylaxis
of MRSA infections. Indeed, bacteriophages (or phages) are viruses that exclusively infect bacteria,
and can, therefore, be considered as their natural killers. Although phages have been used to fight
infectious diseases in Eastern Europe since the early 20th century (phage therapy), it is only in the last
decade that they have resurged as an alternative against multidrug-resistant bacteria [12]. Moreover,
phage lytic proteins (endolysins) are also promising candidates as new antimicrobials. Endolysins
are phage-encoded peptidoglycan hydrolases that act during the latter stages of the lytic cycle to
break down the cell wall, and as a result, lyse the host cell to release the newly formed viral particles.
These proteins represent a novel class of antibiotics named enzybiotics that selectively and rapidly
kill specific Gram-positive bacteria when added externally to cells [13]. In addition, the potential for
development of bacterial resistance is considered very low, due probably to the fact that they target the
highly conserved peptidoglycan bonds [14]. For several endolysins, a synergistic effect with antibiotics
has also been demonstrated [15]. Additionally, the efficacy of endolysins has been studied in various
animal models of infection with promising results [16]. Regarding their safety and toxicity, a detailed
study carried out with two pneumococcal endolysins, Pal and Cpl-1, reported no change in gene
expression for human macrophages and pharyngeal cells exposed to endolysins. Likewise, mice injected
with these proteins exhibited no physical or behavioral changes, no hypersensitivity or allergic reaction,
constant pro-inflammatory cytokine levels and no significant changes in the fecal microbiome [17].
Moreover, the main drawback of endolysins, i.e., their lack of activity against Gram-negative bacteria,
has already been overcome by developing fusion proteins that consist of an endolysin plus a cationic
peptide (Artilysin®) [18] or an endolysin plus a bacteriocin (lysocins) [19]. Given their enormous
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therapeutic potential, there is a growing number of studies regarding the activity of endolysins
against S. aureus strains. For example, endolysin SAL-1, derived from the Staphylococcus-specific
bacteriophage SAP-1 (the active pharmaceutical ingredient of SAL200) is being evaluated in clinical
trials for the treatment of antibiotic-resistant staphylococcal infections [20]. Additionally, endolysin
CF-301 (ContraFect) is now in phase 2 clinical trials for bacteremia and endocarditis treatment [21].
In our previous work, we identified and characterized four S. aureus-infecting phages: two siphophages,
phiIPLA88 and phiIPLA35, and two myophages, phiIPLA-RODI and phiIPLA-C1C [22,23]. Characterization
of phiIPLA-RODI revealed that it is a broad-host-range phage, able to infect several species belonging
to the Staphylococcus genus [23]. Moreover, genomic analysis of this phage led to the identification of
an endolysin, LysRODI, which contains two catalytic domains (CHAP and amidase-2 domain) and one
cell wall-binding domain (CBD), SH3b [23,24]. Our laboratory has already demonstrated the potential
of several phage endolysins to remove S. aureus cells from different environments. For example,
various endolysins and chimeric proteins showed lytic activity against S. aureus cells in pasteurized
milk [25,26] and biofilms [24,27,28]. Moreover, we showed that subinhibitory doses of some endolysins
can inhibit biofilm formation in S. aureus through the downregulation of autolysin-encoding genes [28].
More recently, we showed the ability of some of these proteins (LysRODI, LysA72 and CHAPSH3b) to
remove staphylococcal strains in vivo. Indeed, LysRODI and CHAPSH3b were non-toxic in a zebrafish
embryo model and significantly reduced mortality in a zebrafish model of systemic infection [24].
Moreover, LysRODI demonstrated great efficacy in preventing mammary infections by S. aureus and
S. epidermidis in a mouse model of mastitis [24]. However, most of these studies were carried out
with MSSA strains. In the present work, we characterized a set of MRSA strains, some of which were
isolated from patients with active infections and some from asymptomatic carriers. Then, we assessed
their susceptibility to bacteriophages phiIPLA-RODI and phiIPLA-C1C, and endolysin LysRODI.
We further aimed to determine whether there was any correlation between different traits of these
strains and their susceptibility to this protein. Ultimately, we think that this information will help us to
reach our long-term goal of optimizing the use of phage-derived endolysins to treat MRSA infections.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
All the MRSA strains (Table 1) were isolated by the Microbiology Service at San Agustín Hospital
(Avilés, Asturias, Spain) from November 2018 to October 2019. Isolation was carried out on blood agar
medium and methicillin resistance was determined by the vitek2 system (Biomerieux). Strains were
routinely grown in tryptic soy broth (TSB; Difco, Franklin Lakes, NJ) at 37 ◦C with shaking at 200 rpm
or on plates containing TSB supplemented with 2% (wt/vol) bacteriological agar (TSA).
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Table 1. Genotypic and phenotypic characteristics of clinical MRSA isolates.






Formation * Virulence/Resistance Genes *
1 Ulcer exudate + HA A S 0.869 ± 0.060 1.208 ± 0.736 ebpS, fib, cap5, seg, sei, PVL/LfxR
2 Ulcer exudate + HA C S 0.778 ± 0.019 1.069 ± 0.611 cna, cap5, sec, seg, sei, eta, etb, PVL/LfxR
3 Ulcer exudate + HA A S 0.256 ± 0.020 0.627 ± 0.469 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
4 Ulcer exudate + CA B S 0.506 ± 0.173 1.084 ± 0.739 fnbB, fib, cap5, see, seg, sei, eta, etb, PVL
5 Urine + HA A S 0.895 ± 0.053 1.458 ± 0.773 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
6 Ulcer exudate + HA A S 0.592 ± 0.058 0.995 ± 0.344 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
7 Ulcer exudate + HA A S 0.439 ± 0.047 0.872 ± 0.559 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
8 Ulcer exudate + HA A S 0.330 ± 0.040 1.334 ± 0.895 fib, cap5, seg, sei, eta, etb, PVL/LfxR
9 Ulcer exudate - HA A S 0.345 ± 0.025 1.765 ± 0.618 ebpS, fib, cap5, seg, sei, eta, etb/CLIR
10 Ulcer exudate + HA A S 0.409 ± 0.017 1.506 ± 0.343 ebpS, fib, cap5, seg, sei, eta, etb/LfxR, CLIR
11 Conjunctival exudate ND ND C R 1.136 ± 0.097 0.895 ± 0.552 cna, ebpS, cap5, seg, sei, eta, etb/LfxR
12 Ulcer exudate + HA A S 0.101 ± 0.030 1.196 ± 0.896 fib, cap5, seg, sei, eta, etb, PVL/LfxR
13 Wound exudate - HA B S 0.281 ± 0.127 1.353 ± 0.885 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
14 Ulcer exudate + HA A S 0.564 ± 0.043 2.236 ± 0.720 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR, CLIR
15 Ulcer exudate + HA C S 0.458 ± 0.044 1.861 ± 0.348 cna, ebpS, cap5, seg, sei, eta, etb, PVL/LfxR*
16 Ulcer exudate + HA A R 0.380 ± 0.030 0.954 ± 0.389 fib, cap5, seg, sei, eta, etb, PVL/LfxR
17 Ulcer exudate + HA B S 0.910 ± 0.144 1.375 ± 0.694 ebpS, fib, cap5, seg, sei, eta, etb/LfxR
18 Ulcer exudate - HA B S 0.619 ± 0.076 0.804 ± 0.496 ebpS, fnbB, fib, cap5, seg, sei, eta, PVL/LfxR
19 Urine - HA A R 0.681 ± 0.076 2.300 ± 0.324 ebpS, fib, cap5, sed, see, seg, sei/LfxR
20 Eschar exudate - HA C S 0.569 ± 0.121 1.630 ± 0.796 cna, cap5, seg, sei, eta, etb, PVL/LfxR, CLIR
21 Blood culture + CA B R 0.771 ± 0.099 1.781 ± 0.441 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
22 Blood culture + HA C S 0.427 ± 0.109 0.626 ± 0.474 cna, fnbA, cap5, seg, sei, PVL/LfxR
23 Urine - CA A S 1.068 ± 0.081 0.828 ± 0.291 ebpS, fib, cap5, sed, see, seg, sei, eta, etb, PVL/LfxR
24 Nasal exudate - HA A R 0.800 ± 0.041 2.214 ± 0.519 ebpS, fib, cap5, sed, see, seg, sei, eta, etb, PVL/LfxR
25 Nasal exudate - HA D S 1.364 ± 0.153 0.786 ± 0.421 cna, fnbA, fnbB, cap5, seg, sei, czr/LfxR
26 Eschar exudate - HA C R 0.575 ± 0.062 1.143 ± 0.401 cap5, sed, see, seg, sei, eta, etb, PVL/LfxR
27 Nasal exudate - CA A R 0.614 ± 0.034 0.739 ± 0.347 ebpS, fib, cap5, seg, sei, eta, etb/LfxR
28 Nasal exudate - HA E S 1.755 ± 0.169 0.892 ± 0.317 ebpS, fnbA, fib, cap5, sec, seg, sei
29 Sputum ND ND A S 0.857 ± 0.093 2.287 ± 0.322 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR, CLIR
30 Eschar exudate - HA A S 0.566 ± 0.100 1.384 ± 0.275 ebpS, fib, cap5, sed, see, seg, sei, eta, etb/LfxR, CLIR
31 Urine + HA B S 1.076 ± 0.083 1.160 ± 0.456 ebpS, fib, cap5, seg, sei, eta, etb/LfxR
32 Nasal exudate - HA B S 0.316 ± 0.054 0.979 ± 0.309 fnbA, fnbB, fib, cap5, seg, sei, PVL/LfxR
33 Wound exudate + HA A S 1.115 ± 0.311 0.919 ± 0.146 ebpS, fib, cap5, sed, seg, sei, eta, etb/LfxR
34 Ulcer exudate + HA A R 0.383 ± 0.045 0.693 ± 0.646 ebpS, fib, cap5, sed, seg, sei, eta, etb, PVL/LfxR
35 Nasal exudate - HA A R 0.456 ± 0.121 1.131 ± 0.360 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
36 Eschar exudate - HA A R 0.884 ± 0.048 0.555 ± 0.325 ebpS, fib, cap5, sed, seg, sei, eta, etb/LfxR
37 Wound exudate - HA A S 0.333 ± 0.035 1.288 ± 0.615 ebpS, fib, cap5, seg, sei, eta, etb/LfxR
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Table 1. Cont.






Formation * Virulence/Resistance Genes *
38 Pericatheter + HA A S 0.946 ± 0.008 1.326 ± 0.440 ebpS, fib, cap5, sed, seg, sei, eta, etb, PVL/LfxR
39 Ulcer exudate + HA A S 0.576 ± 0.061 0.992 ± 0.408 ebpS, fib, cap5, seg, sei, eta, etb, PVL
40 Abscess + HA E S 1.100 ± 0.105 0.985 ± 0.338 bbp, cna, ebpS, fnbA, cap8, seg, sei, PVL
41 Nasal exudate - HA A S 0.121 ± 0.019 0.648 ± 0.235 ebpS, fib, cap5, seg, sei, eta, etb/LfxR
42 Ulcer exudate + HA C S 0.913 ± 0.221 0.893 ± 0.447 cna, fnbA, cap5, cap8, seg, sei/LfxR
43 Abscess + HA A S 0.363 ± 0.039 0.882 ± 0.484 ebpS, fnbA, fib, cap5, cap8, seg, sei/LfxR
44 Pharyngeal exudate - HA A S 0.964 ± 0.068 0.865 ± 0.430 ebpS, fnbA, fib, cap5, sed, seg, sei, czr/LfxR
45 Nasal exudate - HA A S 0.108 ± 0.015 1.571 ± 0.465 ebpS, fib, cap5, seg, sei, eta/LfxR
46 Blood + HA A S 1.433 ± 0.091 1.043 ± 0.840 ebpS, fib, cap5, sed, seg, sei/LfxR, CLIR
47 Urine + CA A R 0.366 ± 0.047 2.214 ± 0.788 ebpS, fib, cap5, seg, sei, eta, etb/LfxR
48 Abscess + HA B S 0.102 ± 0.023 1.350 ± 0.353 fnbB, fib, cap5, seg, sei, eta, PVL/LfxR
49 Telescoping catheter - HA A R 1.418 ± 0.080 2.361 ± 0.863 ebpS, fnbA, fib, cap5, seg, sei, czr/LfxR, CLIR
50 Ulcer exudate + HA F S 0.654 ± 0.126 1.301 ± 0.339 ebpS, fib, cap5, sed, seg, sei, eta, etb, PVL/LfxR
51 Ulcer exudate - HA A R 0.353 ± 0.052 1.683 ± 0.482 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
52 Abscess + CA B S 0.528 ± 0.136 1.404 ± 0.562 fnbB, fib, cap5, seg, sei, eta, PVL/LfxR
53 Ulcer exudate + HA C S 0.213 ± 0.035 1.000 ± 0.186 cna, cap5, sec, seg, sei, eta, etb, PVL/LfxR
54 Ulcer exudate + HA A S 0.353 ± 0.035 1.398 ± 0.566 ebpS, fib, cap5, seg, sei, PVL/LfxR, TMP/SMXR
55 Ulcer exudate + CA A R 1.007 ± 0.083 1.204 ± 0.608 ebpS, fib, cap5, seg, sei, PVL/LfxR
56 Ulcer exudate + CA A S 0.072 ± 0.021 2.583 ± 0.572 ebpS, fib, cap5, seg, sei, eta, etb, PVL/LfxR
57 Wound exudate + CA B R 0.218 ± 0.031 0.905 ± 0.416 fnbB, fib, cap5, seg, sei, PVL
58 Wound exudate + HA C S 0.769 ± 0.055 0.879 ± 0.398 cna, cap5, sec, eta, etb, PVL/LfxR
59 Ulcer exudate + HA A S 0.253 ± 0.031 1.561 ± 0.417 ebpS, fib, cap5, PVL/LfxR
60 Wound exudate + HA D S 1.001 ± 0.089 1.463 ± 0.147 cna, fnbB, cap5, eta, etb, PVL, czr/LfxR, CLIR
61 Wound exudate + HA B R 0.163 ± 0.030 1.718 ± 0.622 ebpS, fib, cap5, eta, etb/LfxR
62 Ulcer exudate + HA A R 0.584 ± 0.141 1.223 ± 0.720 ebpS, fib, cap5, eta, etb/LfxR
63 Wound exudate + HA A R 0.169 ± 0.071 1.307 ± 0.655 ebpS, fib, cap5, PVL/LfxR
64 Urine + HA A S 0.335 ± 0.013 1.133 ± 0.625 ebpS, fib, cap5, eta, PVL/LfxR, CLIR
65 Wound exudate - HA A R 0.325 ± 0.005 1.280 ± 0.456 ebpS, fib, cap5, sed, eta/LfxR, CLIR
66 Urine + HA A S 0.444 ± 0.358 2.102 ± 0.704 ebpS, fib, cap5, eta, PVL/LfxR
67 Ulcer exudate + HA A R 0.397 ± 0.024 1.575 ± 0.444 ebpS, fib, cap5/LfxR
* Relative specific activity shows the means and standard deviations of specific activity values of the different strains compared to reference strain Sa9. Biofilm formation shows the means
and standard deviations of A595 values from three independent experiments of crystal violet staining. Genes eno, clfA, clfB, icaA, icaD, tst and mecA were present in all the strains.
HA: hospital associated origin. CA: community associated origin. LfxR: levofloxacin resistance. CLIR: clindamycin resistance. TMP/SMXR: trimethopim/sulfamethoxazole (cotrimoxazol)
resistance. ND: not determined.
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2.2. DNA Preparation and Genomic Analysis
Total DNA from the MRSA strains was extracted by using the GenElute Bacterial Genomic DNA
Kit (Sigma-Aldrich, Madrid, Spain) according to the manufacturer’s recommendations and while
supplementing the lysis solution with 5 mg/mL lysozyme and 0.2 mg/mL lysostaphin. The DNA
concentration and the A260/A280 purity ratio were determined by using a Nanophotometer™ (Implen
GmbH, Munich, Germany).
The detection of virulence and antimicrobial resistance genes was carried out by PCR in a
thermocycler (Bio-Rad, Hercules, CA) using Taq 2 ×Master Mix RED, 1.5 mM MgCl2 (Ampliqon A/S,
Odense, Denmark) and the primers shown in Table 2. All PCR products were resolved by electrophoresis
in 2% agarose gels, stained with EZ-Vision® One (VWR, Barcelona, Spain) and visualized under UV
light with a G:BOX gel documentation system (Syngene, Cambridge, UK) equipped with GeneSys
image acquisition software (Syngene). A 1-kb DNA ladder (Nippon Genetics, Dueren, Germany) was
included in all gels.
Random amplification of polymorphic DNA (RAPD) analysis of the different isolates was
performed using primer OPL5 (5’-ACGCAGGCAC-3’) according to a previously described method [29].
The resulting RAPD-PCR band patterns were then analyzed by agglomerative hierarchical clustering
using the unweighted pair group method with arithmetic averages (UPGMA) based on the Jaccard
similarity coefficient. The cophenetic correlation coefficient was calculated to determine the goodness
of fit of the dendrogram. The selection of cut-off points for defining clusters was based on the default
values determined by SciPy 1.0.0, and the shapes of the dendrograms.
2.3. Biofilm Formation Assays
Biofilms were grown in 96-well microtiter plates (Thermo Scientific, NUNC, Madrid, Spain)
according to the method described by Herrera et al. [30] with some modifications. Briefly, overnight
cultures of S. aureus were diluted in TSBg (TSB supplemented with 0.25% w/v d-(+)-glucose) to obtain
cell suspensions each containing 106 CFU/mL; 0.2 mL aliquots of this suspension were used to inoculate
each well; 0.2 mL of TSBg was added to the control well. These microtiter plates were then incubated
for 24 h at 37 ◦C. Following incubation, the planktonic phase was removed; the adhered phase was
washed twice with phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4
and 2 mM KH2PO4; pH 7.4) and subsequently stained with crystal violet. Staining was performed
by adding 0.2 mL of 0.1% (w/v) crystal violet to each well. Following 15 min of incubation at room
temperature, the excess dye was removed by washing twice with water. The crystal violet attached to
the well was distained with 0.2 mL of 33% (v/v) acetic acid and absorbance at 595 nm was quantified
with a Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad Laboratories, Hercules, CA,
USA). This experiment was performed with three independent biological replicates.
2.4. Quantification of Specific Lytic Activity
Protein LysRODI was expressed and purified as described previously [23]. Turbidity reduction
assays were performed using MRSA cells suspended in NaPi buffer (50 mM; pH = 7.4) and treated
with two-fold dilutions of the purified protein (0.02–50 µM). Those data allowed calculation of the
specific lytic activity (∆OD600 ×min−1 × µM−1). The results were then divided by the specific activity
of the reference strain S. aureus Sa9 to calculate the relative specific lytic activity. This allowed the
correction of differences in the specific activity values that might have been due to the use of different
protein stocks. All experiments were performed in triplicate.
2.5. Phage Susceptibility
The ability of phages phiIPLA-RODI and phiIPLA-C1C to infect and lyse the different isolates
was analyzed by performing spot tests. Briefly, 1:10 dilutions from overnight cultures of the different
strains were used to inoculate a lawn in semisolid agar on top of a TSA plate. Once the top layer
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containing the bacterial cells was set, 10 µL droplets of each phage suspension were placed onto the
plate and allowed to air dry. Then, the plates were incubated overnight at 37 ◦C and the results were
visualized the following day. A strain was considered susceptible (S) only if a clear halo was visible;
otherwise, the strain was considered resistant (R).
Table 2. Conditions of the PCR reactions used for the identification of virulence genes.
Virulence factor Gene (pb) Primers Reference
Bone sialoprotein binding protein bbp (575) BBP-1, BBP-2
[31]
Collagen binding protein cna (423) CNA-1, CNA-2
Laminin binding protein eno (302) ENO-1, ENO-2
Elastin binding protein ebpS (186) EBP-1, EBP-1
Fibronectin binding protein fnbA (643) FNBA-1, FNBA-2
fnbB (524) FNBB-1, FNBB-2
Fibrinogen binding protein fib (404) FIB-1, FIB-2
Clumping factor clfA (292) CLFA-1, CLFA-2
clfB (205) CLFB-1, CLFB-2
Capsule cap5 (361) Cap5 k1, Cap5 k2 [32]
cap8 (173) Cap8 k1, Cap8 k2
Polysaccharide matrix icaA (1315) icaA-R, icaA-R
[33]icaD (381) icaD-F, icaD-R
Proteinaceous matrix bap (971) BAP-sasp-6m,BAP-sasp-7c
Enterotoxins
sea (127) SEA3, SEA4
[34]
seb (477) SEB1, SEB4
sec (271) SEC3, SEC4
sed (319) SED3, SED4
see (178) SEE3, SEE2
seg (287) SEG1, SEG2
[35]seh (213) SEH1, SEH2
sei (454) SEI1, SEI2
Toxic shock syndrome toxin tst (445) TST3, TST6
[34]
Exfoliative toxins
eta (119) ETA3, ETA4
etb (262) ETB3, ETB4
Panton-Valentine leukocidin PVL (505) PVL505-F,PVL505-R
[36]Cadmium and zinc resistance czr (655) czrC-F, czrC-R
Methicillin resistance mecA (264) mecA264-F,mecA264-R
Quaternary ammonium




Data analysis and representation were performed using modules NumPy 1.15.0, pandas 0.23.3,
SciPy 1.0.0, matplotlib (v.2.0.2) and scikit-learn 0.19.2 in Python 3.5.3. The independence of two
categorical variables was assessed using the Chi-square test. Clustering of the biofilm and the relative
specific lytic activity data was carried out with the k-means algorithm.
3. Results
3.1. Isolation of MRSA Strains at San Agustín Hospital
Throughout the period under study, 67 MRSA isolates were isolated from specimens taken from
patients with ages between 17 and 95 years old, with the mean age being 75 years. The MRSA-positive
individuals included 37 (44.78%) males and 30 (55.22%) females. Isolates were collected from 40
outpatients (59.70%) and 27 inpatients (40.30%). Among those MRSA isolates, 38.81% (25 strains)
came from ulcer exudates, 14.93% (eight strains) from wound exudates, 11.94% (seven strains) from
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nasal exudates, 10.45% (seven strains) from urine samples, 5.97% (four strains) from eschar exudates,
5.97% (four strains) from abscesses, 4.48% (three strains) from blood cultures, 2.99% (two strains) from
catheters, 1.49% (one strain) from conjunctival exudate, 1.49% (one strain) from pharyngeal exudate
and 1.49% (one strain) from sputum (Table 1). It must be noted that 43 strains came from people with
staphylococcal infections, while 22 were isolated from asymptomatic carriers (Table 1). In relation to
the type of MRSA strain, 56 corresponded to hospital-associated strains, while nine were community
acquired (Table 1). Regarding antibiotic resistance, most isolates (61) were resistant to levofloxacin,
11 were resistant to clindamycin and only one was resistant to trimetropim/sulfametoxazol (Table 1).
Analysis of the independence between these characteristics revealed an association between the
existence or not of an infection and the sample type (Chi-square = 103.236, degrees of freedom (dof) = 20,
p value = 3.304 × 10−13). For instance, all nasal, eschar and pharyngeal specimens were taken from
asymptomatic carriers, whereas all blood and abscess samples came from infected patients (Figure 1A).
There was also a link between the origin of the isolates and the type of clinical sample (Chi-square =
72.076, degrees of freedom (dof) = 20, p value = 8.315 × 10−8). In this case, the proportion of strains
from certain types of specimens also differed between community-associated and hospital-associated
isolates (Figure 1B). No association was observed between the existence or not of an active infection and
the origin of the isolates, nor was there any link between antibiotic resistance and any of these features.
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3.2. Genetic Diversity of Human MRSA Isolates
To investigate the relationship between isolates, we first performed genomic fingerprinting
analysis by RAPD-PCR. Amplification with primer OPL5 revealed the presence of six different band
patterns, with bands ranging between 200 bp and 1700 bp in size (Figure 2A). The relative abundances
of the six RAPD profiles (A, B, C, D, E and F) varied between the analyzed samples, with A being the
most frequent (62.69% of the samples). The relative frequencies of profiles B, C, D, E and F were 16.42%,
13.43%, 2.99%, 2.99% and 1.49%, respectively. The band patterns of the different RAPD profiles were
used to perform hierarchical clustering, whose results were subsequently plotted as a dendrogram.
Considering a cut-off value of 0.399, the profiles appeared clustered in one large cluster that could be
further subdivided in two groups, with one including profiles A, F and D and the other corresponding
to profiles E and B (Figure 1A). Profile C was an orphan cluster (Figure 2A). The cophenetic correlation
coefficient was 0.787, indicating that the dendrogram was a good representation of the dissimilarities
between the observed band patterns.
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Figure 2. Dendrograms representing clustering analysis of clinical MRSA strains by UPGMA using the
Jaccard similarity coefficient. (A) Clustering based on RAPD-PCR. The blue line represents strains that
were not included in any cluster (isolates with RAPD (Random amplification of polymorphic DNA)
profile (C). Separate clusters are shown in different colors. The cut-off value for clustering was 0.399.
A, B, C, D, E and F represent the six distinct RAPD profiles. The numbers in brackets indicate how
many strains have each profile. (B) Clustering based on RAPD profile plus the possession or not of
certain virulence and resistance genes. Separate clusters appear in different colors. The cut-off value
for clustering was 0.58.
To further characterize the MRSA isolates, we examined the presence of genes encoding different
virulence factors and antimicrobial resistance determinants (Table 1). The entire collection of isolates
was phenotypically resistant to methicillin and harbored the mecA gene. By contrast, none of them
carried the qacA/B gene, and only four strains (5.97%) possessed gene czr. We also identified the
presence of genes encoding microbial surface components recognizing adhesive matrix molecules
(MSCRAMMs). All 67 isolates were positive for genes eno, clfA and clfB. In turn, genes bbp, cna, ebpS,
fnbA, fnbB and fib were respectively present in 1.49%, 16.42%, 74.63%, 13.43%, 11.94% and 82.09% of all
strains. Regarding genes involved in capsule formation, all strains analyzed, except MRSA-IPLA40,
carried the cap5 gene (98.51%), while only three (MRSA-IPLA 40, 42 and 43; 4.48%) possessed gene
cap8. Additionally, some genes involved in biofilm formation (icaA and icaD) were present in 100%
of the strains analyzed, while none had the bap gene. Regarding toxin-encoding genes, only tst was
present in 100% of the strains, whereas sea and seb were not detected in any isolate. The rest of the
toxin-encoding genes, namely, sec, sed, see, seg, sei, eta, etb and PVL, were respectively carried by 5.97%,
19.40%, 8.96%, 85.07%, 85.07%, 73.13%, 62.69% and 62.69% of all strains.
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Using the data regarding the RAPD profile and the presence or absence of the genes that showed
variation between strains, we attempted new clustering of the isolates. In this case, the strains were
grouped into three clusters when using a cut-off of 0.58 (Figure 2B). The green (cluster I) and red (cluster
II) clusters consisted mostly of the nine strains with the C RAPD profile, together with the two strains
with profile D (one in the green cluster and one in the red cluster) and one with profile E in the green
cluster. In turn, the cyan cluster (cluster III) included all the strains with RAPD profiles A, B and F,
and one strain with profile E. Therefore, cluster III corresponds largely to the large cluster of Figure 2A,
with the exception of a few strains from the low frequency RAPD profiles, which are included in
clusters I and II. The cophenetic correlation coefficient was 0.725, indicating that the dendrogram was
a good representation of the genetic differences observed between the strains.
In order to infer whether there was any relationship between the origins of the strains and their
genetic profiles, we examined the independence between their RAPD profile and other variables (type of
clinical sample, active infection, origin (community/hospital), antibiotic resistance). For most variables,
this analysis showed that there was no significant correlation with the RAPD profile, the only exception
being levofloxacin resistance (Chi-square = 23.568, degrees of freedom (dof) = 5, p value = 0.0003).
Thus, all isolates with RAPD profiles D and F were resistant to this antibiotic, whereas isolates with the
E profile were susceptible (Figure 3).
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Figure 3. Stacked bar charts representing the number of strains with susceptibility or resistance to
levofloxacin that have the different RAPD profiles.
3.3. Biofilm Formation Ability
Following genetic characterization, we analyzed the abilities of the MRSA clinical strains to form
biofilms on a polystyrene surface. The biomass values obtained f r the 67 strains r nged be ween
0.555 (MRSA-IPLA 36) and 2.583 (MRSA-IPLA 56), so it was considered t at all were capable of
forming biofilms, although with different strengths. The strains were th n grouped into three clusters,
namely, weak (bio ass ≤ 1.143), average (biomass between 1.143 and 1.861) and strong (biomass
≥ 1.861) biofilm form rs, by using the k-means algorithm (Figur 4A). Strains with poor abilities to
develop biofilms (cluster 0) repr sented 44.78% of the total sample. The second largest cluster was
number 1 (41.79%), which consisted of isolates with average biofilm forming capacity. Finally, cluster 2,
including the strong biofilm-forming strains, corresponded to just 13.43% of all isolates.
Next, we studied the dep ndence between biofilm-formi g strength (w ak, average or str ng)
and pr viously characterized parameters (type of sample, infection, origin, RAPD profile, presence
of different genes and antibiotic resistance) by performing a Chi-square test. Most of these variables
showed no significant co-dependence with biofilm development. The only exception was the presence
of gene fnbA (p value = 0.011). To get a closer look at this potential correlation, we examined the
frequency of fnbA in the three biofilm clusters (Figure 4B). The results of this analysis indicated that
this gene was only present in weak (26.67%) and strong (11.11%) biofilm formers but not in average
biofilm-forming isolates.
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3.4. Susceptibility to Phages phiIPLA-RODI and phiIPLA-C1C
The results obtained in the phage susceptibility experiments revealed that all strains were resistant
to phage phiIPLA-C1C, while the impact of phiIPLA-RODI varied between isolates (Table 1). Thus,
29.85% of the strains were resistant to the phage and 70.15% were susceptible. The existence of potential
co-dependence between phiIPLA-RODI susceptibility and other parameters (type of sample, infection,
origin, RAPD profile, biofilm formation, presence of different genes and antibiotic resistance) was
examined, but no potential correlation was found.
3.5. Susceptibility to Endolysin LysRODI
The susceptibility of the different MRSA isolates to endolysin LysRODI was determined by
carrying out the turbidity reduction assay, which generally gives more precise results than the MIC
assay for this type of antimicrobials. To do that, we added a concentration of 13.44 µg/mL (0.25 µM)
of LysRODI per well, which led to a clear turbidity reduction in the reference strain S. aureus Sa9.
The results of these assays allowed for the calculation of the specific lytic activity for each strain;
those values were then divided by that of strain Sa9 to determine the relative specific lytic activity.
The values obtained are shown in Table 1, and they demonstrate that all isolates exhibited lysis by
LysRODI, but with different degrees of susceptibility. These values were then used to classify the
strains into three clusters corresponding to isolates with low (cluster 0), average (cluster 1) and high
(cluster 2) susceptibility (Figure 5A). The largest clusters, corresponding to 62.69% and 31.34% of all
isolates, included strains with low and average endolysin susceptibility, respectively. By contrast,
only 5.97% of the isolates were more susceptible to LysRODI than the reference strain Sa9.
As we did with the biofilm data, we examined whether there was independence between endolysin
susceptibility and other parameters (type of sample, infection, origin, RAPD profile, biofilm formation,
presence of the different genes analyzed and antibiotic resistance). Again, most of the variables
analyzed and endolysin susceptibility were independent according to the result of the Chi-square test.
Nonetheless, others were not independent from LysRODI susceptibility, including the RAPD profile
(p value = 0.022), fnbA (p value = 0.007), eta (p value = 0.002), etb (p value = 0.024), PVL (p value = 0.024)
and czr (p value = 0.0002). For this reason, we assessed more in detail the frequency distribution of
these parameters in the three groups of susceptibility. In the case of the RAPD profiles, strains with low
susceptibility exhibited RAPD A (69.05%), B (19.05%) or C (11.90%) patterns, whereas strains with high
susceptibility had RAPD A (50%), RAPD D (25%) or RAPD E (25%) profiles (Figure 5B). The cluster
corresponding to average susceptibility included isolates with all six RAPD profiles. It is worth noting
that low frequency profiles (F, D and E) exhibited average or high susceptibility, while more frequent
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RAPD profiles (A, B and C) largely had low or average susceptibility. The percentage of strains
carrying fnbA for each cluster was 7.14%, 14.28% and 75% for strains with low, average and high
susceptibility, respectively (Figure 5C). The relative frequency distribution of strains with and without
genes eta, etb and PVL was very similar (Figure 5D–F). For example, in the case of eta, the gene was
present in strains exhibiting low or average endolysin susceptibility at 80.95% and 71.43%, respectively.
Conversely, none of those three genes was detected in the four strains with high susceptibility. Finally,
gene czr was absent from all strains with low LysRODI susceptibility, whereas some strains with
average (9.52%) and high (50%) susceptibility did carry the gene (Figure 5G).Antibiotics 2020, 9, x 7 of 20 
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4. Discussion
Infections caused by multidrug-resistant MRSA strains are becoming more and more frequent
in hospitals all over the world. This represents a serious threat to healthcare practice, especially
considering the immunological vulnerability of many hospitalized patients and their difficulty with
fighting infections that are practically untreatable with conventional antimicrobials. Therefore, there
is an urgent need for new therapeutic agents and control strategies to prevent the transmission and
development of these infections. Amongst the multiple strategies aimed at combatting drug-resistant
bacteria, the use of phage-based therapies represents a feasible, safe alternative to more conventional
drugs. Within this context, the present work sought to evaluate the antimicrobial activities of two
staphylococcal phages (phiIPLA-RODI and phiIPLA-C1C) and one endolysin (LysRODI) against MRSA
strains from clinical origin, with a view to their future therapeutic use.
The first part of this study involved the collection of 67 MRSA isolates over a 12-month period in
a medium-size hospital (428 beds) from different types of clinical specimens. In spite of the samples’
diverse clinical origins, the isolates seemed to be genetically related based on their RAPD-PCR patterns
and virulence gene content, with one large cluster including most of the strains, and two smaller
clusters comprising strains with RAPD profile C and a few isolates with low frequency profiles.
The predominant genetic pattern was RAPD profile A, although no correlation could be found between
a specific genetic pattern and the origin of the sample from which it was isolated. This lack of genetic
diversity is not surprising, as about 90% of all studied S. aureus MRSA genomes can be grouped into four
major clonal complexes (CC5, CC8, CC398 and CC30) [37]. Overall, all the strains had a good arsenal
of virulence genes, with some of them bearing important implications in disease prognosis, such as the
different toxins. Moreover, most of these isolates exhibited not only resistance to methicillin but also
resistance to other antibiotics, especially levofloxacin. The accumulation of resistance determinants in
this pathogen is very frequent, and is making treatment of staphylococcal infections an increasingly
difficult task.
Additionally, we studied the abilities of these strains to form biofilms. This characteristic, widely
spread amongst S. aureus strains, may negatively contribute to bacteria eradication, allowing the
pathogen to survive in different environments and cause chronic infections. Somewhat unsurprisingly,
all the analyzed strains were able to form biofilms on polystyrene surfaces. Infections caused by
bacteria living in biofilms are more difficult to treat because cells embedded within a matrix are more
resistant to antibiotics and the immune system than planktonic cells. The biofilm matrix prevents
antibiotics from reaching their target due to low diffusion. Moreover, the altered metabolism of sessile
bacteria makes them more tolerant to antibiotics [38]. Given that all the isolates carried the ica genes
but not the bap gene, we can hypothesize that the biofilm matrix of these strains might be mainly
composed of polysaccharides [39]. Additionally, most of the isolates carried other virulence factors
involved in the binding of bacteria to biotic surfaces, like human tissues. Due to their role in biofilm
formation on host tissues, possession of these proteins further increases the difficulty of infection
treatment. As a result, they are considered potential drug targets to curtail the development of chronic
infections [40]. Although still concerning from a clinical standpoint, it is worth noting that strong
biofilm-forming strains represented the lowest percentage amongst the strains examined in this study.
Interestingly, two strong biofilm formers, 38 and 49, were isolated from catheters, in which their good
biofilm-forming capability may help them to successfully colonize medical implants.
Bacteriophages have already been proven successful for the treatment of MRSA infections affecting
skin and soft tissues [41], septicaemia [42] and wounds [43]. Here, we tested the lytic activities of two
myophages, phiIPLA-RODI and phiIPLA-C1C, against the 67 MRSA clinical isolates. Myoviridae phages
generally exhibit a broad host range and are, therefore, preferred candidates for phage therapy [44].
None of the strains were susceptible to phage phiIPLA-C1C, which is not surprising as this phage
predominantly infects S. epidermidis strains [23]. In contrast, 70% of all isolates displayed susceptibility
to phiIPLA-RODI. In a previous study, this phage showed activity against 21 S. aureus strains as well
several strains belonging to other staphylococci [23]. Although this phage can be potentially used in
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phage cocktails or in combination with antibiotics to kill susceptible strains, it still would not work by
itself against all MRSA isolates.
Compared to bacteriophages, endolysins have the advantage of exhibiting a wider spectrum
of activity [12]. To date, several works have demonstrated the high in vitro and in vivo activity of
endolysins against S. aureus isolates from different origins, including clinical staphylococci (revised
by Gutiérrez et al. [45]). The lytic protein used in this study, LysRODI, had been previously shown
to be highly active against different staphylococcal strains [24]. Along the same lines, the data
presented here indicates that all clinical MRSA isolates were susceptible to LysRODI, although to
different degrees. Similarly, the recombinant endolysin HY-133 was highly active against all tested
MSSA and MRSA isolates, including isolates resistant to mupirocin, ceftaroline/ceftobiprole and
borderline oxacillin [46,47]. To further examine the impact of endolysin treatment, the strains were
clustered into three susceptibility groups (low, average and high), the high susceptibility group being
the least numerous. In contrast, while still being lysed by the enzyme, most strains belonged to
the low susceptibility cluster. The degree of endolysin susceptibility in the analyzed strains had a
correlation with the RAPD profile, and with the presence of genes fnbA, eta, etb, PVL and czr. However,
this correlation is not necessarily indicative of causality; that is, the presence or absence of these genes
does not necessarily determine the ability of LysRODI to lyse cells of a given strain. Nonetheless,
the percentage of strains carrying eta, etb and PVL was considerably higher in the low susceptibility
cluster. In contrast, czr was only present in strains with average or high susceptibility. It would be
interesting to examine whether these trends are specific to this isolate collection. If not, the possible
involvement of these genes in endolysin susceptibility should be studied in detail. So far, the factors
that determine the different degree of endolysin susceptibility remain largely unknown. However,
changes in the cell wall composition or structure are known to influence endolysin activity [47].
For instance, it has been shown that WTA composition has an impact on the efficacy of endolysin
PRF-119. In fact, this is the reason why this endolysin is active against S. aureus strains producing
polyribitol phosphate (RboP) wall teichoic acids (WTA), but not against CoNS strains, which produce
polyglycerol phosphate (GroP) WTA [48]. Moreover, Idelevich et al. [49] found that S. aureus strains
producing GroP WTA were less susceptible to PRF-119 than other strains. Modification of the cell
wall structure has also been shown to influence susceptibility to other antimicrobials. For example,
deletion of the msaABCR operon, which reduces cell wall thickness, resulted in decreased resistance
to vancomycin in vancomycin-intermediate S. aureus (VISA). Simultaneously, this mutation also led
to reduced cross-linking due to increased murein hydrolase activity and nonspecific processing of
murein hydrolases. This defect was enhanced by a decrease in teichoic acid content in the msaABCR
mutant [50].
The broad range of action of LysRODI is very promising for the treatment of staphylococcal infections,
especially those due to antimicrobial resistant strains. As mentioned above, most of the isolates collected in
this study were resistant to levofloxacin, clindamycin and/or trimethoprim/sulfamethoxazole in addition to
methicillin. In our collection, only four strains carried the cadmium and zinc resistance gene czr. However,
one of them was isolated from a wound. It is known that the presence of this gene hinders the efficacy
of zinc-based topical agents for the treatment of staphylococcal infections [51]. Nonetheless, this strain
showed an average susceptibility to endolysin LysRODI, thereby making this protein a good candidate
to be used as topical treatment for wound infections. Indeed, topical application of another endolysin,
S25-3, has been shown to decrease the number of intraepidermal staphylococci and the sizes of pustules
in an experimental mouse model of impetigo [52]. Additionally, S. aureus is one of the prevalent
causes of pneumonia, a serious and often difficult to treat disease because of antibiotic resistance.
Here, we isolated two MRSA strains from pharyngeal and sputum samples, both of which were
sensitive to both phiIPLA-RODI and LysRODI, and eight strains from nasal exudates were susceptible
to the endolysin. In a previous work, Xia et al. [53] found that the activity of endolysin LysGH15 could
be increased by combining it with apigenin, a natural flavonoid from fruits and vegetables, for the
treatment of MRSA-caused pneumonia in mice. The two main characteristics of phage endolysins
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are their high specificity towards their target bacteria and the lack of bacterial resistance selection
after repeated exposure. Both properties make them suitable decolonizing compounds, alternatives to
mupirocin, with minimum effects on the surrounding microbiota. Indeed, decolonization of patients
colonized with MRSA proved to be very useful for lowering their risk of infection [54]. Endolysins also
exhibit properties that can be very useful for the treatment of chronic infections. For instance, there is
in vitro evidence of the efficacy of some endolysins against small colony variants (SCVs) of clinical
origin, such as endolysin HY-133 [55], or against persister cells, such as LysH5 [27]. It is important
to note that some endolysins have a synergistic effect with antibiotics, which might help to boost
their efficacy against chronic infections. Some examples include endolysins P128, CF-301 and ClyS,
which turned out to be inhibitory of planktonic and biofilm MRSA cells when combined with oxacillin,
probably due to the increase in cell wall permeability mediated by the endolysin [56–58].
In summary, this work highlights the potential of phage-derived antimicrobial strategies for
the treatment of MRSA infections, and decolonization of asymptomatic carriers. Phages and phage
lytic proteins could, therefore, be used to substitute or enhance the action of antibiotics and become
powerful allies in the race to limit the spread of antibiotic resistance.
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